1. Home
  2. HWH vs GRDX Comparison

HWH vs GRDX Comparison

Compare HWH & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HWH International Inc.

HWH

HWH International Inc.

N/A

Current Price

$1.37

Market Cap

8.5M

Sector

Health Care

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$2.24

Market Cap

7.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HWH
GRDX
Founded
2021
N/A
Country
United States
United Kingdom
Employees
N/A
2
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
7.4M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
HWH
GRDX
Price
$1.37
$2.24
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.7K
109.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$1.92
52 Week High
$7.77
$5.30

Technical Indicators

Market Signals
Indicator
HWH
GRDX
Relative Strength Index (RSI) 47.44 42.66
Support Level $1.33 $2.03
Resistance Level $1.50 $2.84
Average True Range (ATR) 0.12 0.31
MACD 0.01 0.01
Stochastic Oscillator 65.85 30.83

Price Performance

Historical Comparison
HWH
GRDX

About HWH HWH International Inc.

HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: